1. Home
  2. CTMX vs BBNX Comparison

CTMX vs BBNX Comparison

Compare CTMX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$5.40

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$12.46

Market Cap

560.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTMX
BBNX
Founded
2008
2015
Country
United States
United States
Employees
N/A
423
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.2M
560.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CTMX
BBNX
Price
$5.40
$12.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
11
Target Price
$8.86
$26.73
AVG Volume (30 Days)
2.9M
1.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$138,103,000.00
N/A
Revenue This Year
N/A
$35.03
Revenue Next Year
N/A
$33.24
P/E Ratio
$22.58
N/A
Revenue Growth
36.45
N/A
52 Week Low
$0.40
$8.89
52 Week High
$6.35
$32.71

Technical Indicators

Market Signals
Indicator
CTMX
BBNX
Relative Strength Index (RSI) 50.09 29.44
Support Level $5.10 $12.10
Resistance Level $6.25 $15.64
Average True Range (ATR) 0.33 1.02
MACD -0.06 0.30
Stochastic Oscillator 33.18 27.38

Price Performance

Historical Comparison
CTMX
BBNX

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Share on Social Networks: